“The dramatic declines in the cost of sequencing DNA have opened up all sorts of new use cases for this type of technology.”
Kaja Wasik is the co-founder and CSO at Variant Bio, of a global platform that leverages the enormous power of human genetic diversity to discover a new generation of therapeutics. The company’s focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits.
Kaja has spent her career developing novel sequencing platforms and bringing them to market. Before joining Variant Bio she was a co-founder and CSO at Gencove, one of the first companies to provide commercial, low pass whole-genome sequencing. Kaja completed her PhD in molecular biology at Cold Spring Harbor Laboratory and postdoctoral training at the New York Genome Center.